Production of hybrid cell lines secreting antibodies to herpes simplex virus type 2.
Following different immunization schedules we have produced 102 myeloma--spleen cell hybrid lines (30.8% of the total) secreting antibodies to HSV-2 infected cells. The highest yield of hybrids was derived from fusion of myeloma cells with spleen cells from mice sensitized by footpad injection of formalin-inactivated virus and boosted intravenously with the same antigen. To date, twelve of the antibody-producing hybrids have been cloned by limiting dilutions to generate over 100 monoclonal lines reacting specifically with HSV-infected but not with mock-infected cells. Several hybrid lines have also been injected into mice to generate tumors and high titers of anti-HSV-specific antibodies have been detected in ascitic fluids. All of the hybrids so far tested have retained the capacity to secrete anti-HSV antibodies after long-term in culture or repeated passages through mice. Antibodies reacting with cytoplasmic or nuclear antigens in infected cells as well as type-specific and type common antibodies have been detected.
D000818:Animals; D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000917:Antibody Formation; D000956:Antigens, Viral / Q000032:analysis; D002460:Cell Line; D002999:Clone Cells; D006822:Hybrid Cells / Q000276:immunology*; D008214:Lymphocytes; D051379:Mice; D008807:Mice, Inbred BALB C; D009101:Multiple Myeloma; D018139:Simplexvirus / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000956:Antigens, Viral